An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration announced data from tests of the company’s gene therapy Zolgensma had been manipulated.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Novartis named company veteran Victor Bulto as head of the Swiss drugmaker’s U.S. pharmaceuticals business, effective Sept. 1, 2019.
Tubingen, Germany-based CureVac entered a collaboration research agreement with Yale University to focus on lung therapies.
Harvard University and Merck launched a collaboration that will provide significant research funding for up to four years to support immuno-oncology research led by Arlene Sharpe, MD, PhD, at Harvard Medical School (HMS).
Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.
Despite the benefits empathetic responses can deliver, our industry has yet to fully embrace its integration in the digital space.
We do have more power at our fingertips than generations before us. But witnessing the rise of AI and actually experiencing it are two different realities.
Med Ad News spoke with digital guru Fabio Gratton about the present and future of augmented and virtual reality technologies in pharma and healthcare.
AR/VR Special Feature 2019 – Game changer: The role of immersive technologies in the healthcare and pharmaceutical industries
The next decade promises to be an exciting time for science and innovation. Technological advancements are being made on a daily basis and many of these have the potential to directly impact our everyday lives. In fact, technology is changing at such a rate that it can often seem difficult to keep up.
As augmented reality (AR) technology continues to mature, more life science companies are expanding its use, enabling a new class of innovative content for field teams to bring treatments to light. Whether demonstrating a new therapy, showing how a new medical device works or providing details about a complex disease state, AR can improve customer engagement, education and brand differentiation.